Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a national, multicenter, open-label, randomized, phase II/III trial that evaluates the efficacy and safety of favipiravir and ribavirin in the treatment of patients with confirmed COVID-19 observed within 72 hours. Approximately 100 patients will be randomized in 1:1 ratio and divided into two groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment

NCT04981379

Covid19

COMPLETED PHASE3

UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF

NCT05940545

CCHF

UNKNOWN PHASE1/PHASE2

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures

NCT02646111

Hepatitis C

UNKNOWN PHASE3

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

NCT02822794

Hepatitis C Virus Infection

COMPLETED PHASE3

Phase 3 Study of Sofosbuvir and Ribavirin

NCT01497366

Hepatitis C

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The clinical picture of COVID-19 disease is in a broad spectrum, which includes asymptomatic infection, a mild upper respiratory tract infection, respiratory failure, and even severe viral pneumonia with death. The alarming levels of spread and severity of COVID-19 caused a global emergency and this outbreak has been characterized as a pandemic by the World Health Organization (WHO).

Coronavirus entry into host cells is an important determinant of viral infectivity and pathogenesis. SARS-CoV S1 contains a receptor-binding domain (RBD) that specifically recognizes angiotensin-converting enzyme 2 (ACE2) as its receptor. SARS-CoV spike needs to be proteolytically activated at the S1/S2 boundary, such that S1 dissociates and S2 undergoes a dramatic structural change. These SARS-CoV entry-activating proteases include cell surface protease TMPRSS2 and lysosomal proteases cathepsins. These features of SARS-CoV entry contribute to its rapid spread and severe symptoms and high fatality rates of infected patients.

Ribavirin is a guanosine analog that interferes with the replication of RNA and DNA viruses. Ribavirin was used during the Severe Acute Respiratory Syndrome (SARS) outbreak in combination with corticosteroids, which have an anti-inflammatory effect. Favipiravir is a substrate for viral RNA-dependent RNA polymerase (RdRp) and showed anti-influenza virus activity. Favipiravir is effective against other RNA viruses, poliovirus, rhinovirus, and respiratory syncytial virus and evaluated and developed as a broad spectrum anti-RNA virus drug, including lethal RNA virus infections.

According to national guidelines, Favipiravir treatment is applied to COVID-19 infection in Turkey. The main purpose of this study is to obtain efficacy and safety data for ribavirin and favipiravir in the Turkish patient cohort diagnosed with COVID-19.

This study designed as an open-label, multicenter, parallel-group, randomized, phase II/III clinical drug trial.

This study will be conducted in 4 sites.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV2 COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ribavirin Arm

Ribavirin dosage: 200 mg oral ribavirin capsules for 5 days

Regimen: 1200 mg loading dose on day-1 (three capsules in the morning and three capsules in the evening) followed by 800 mg/day maintenance dose (two capsules in the morning and two capsules in the evening) on day-2 to day-5.

Group Type EXPERIMENTAL

Ribavirin Capsules

Intervention Type DRUG

Ribavirin 200 mg capsules

Favipiravir Arm

Favipiravir dosage: 200 mg oral favipiravir tablets for 5 days

Regimen: 2x1600 mg loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.

Group Type ACTIVE_COMPARATOR

Favipiravir

Intervention Type DRUG

Favipiravir 200 mg tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ribavirin Capsules

Ribavirin 200 mg capsules

Intervention Type DRUG

Favipiravir

Favipiravir 200 mg tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female or male patients aged 18 years and older infected with the SARS-CoV-2 virus.
* Patients that have COVID-19 symptoms within 72 hours and have a positive PCR test result.
* Patients in a stable clinical condition and referred as outpatient for COVID-19 infection.
* Patients who sign the informed consent before the any study procedures.

Exclusion Criteria

* Patients who have required hospitalization.
* Patients who have required intensive care.
* Patients who do not sign the informed consent.
* Any condition that in the investigator's judgement might interfere with study procedures or the ability of the patient to adhere to and complete the study.
* Patients who have been participating in any other clinical trial.
* Severe liver failure (Child Pugh score ≥ C, transaminase\>5 times the upper limit of normal (ULN).
* Severe renal failure (GFR ≤30 mL/min/1.73 m2) or continuous dialysis (hemodialysis, peritoneal dialysis) or continuous renal replacement therapy.
* Severe cardiac disease.
* History of hypersensitivity to either ribavirin/favipiravir.
* Pregnant or breast-feeding.
* Patients who cannot use appropriate contraceptive method during and after the study.
* Patients who are treated with any other treatment agent for COVID-19 in the last 90 days.
* Patients who had COVID-19 vaccination.
* Patients who had ribavirin/favipiravir for any reason in the past 72 hours.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No